← All trials
NCT05560282
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 10, 2022
- Primary completion
- Jan 31, 2024
- Completion date
- Jan 31, 2024
- First posted
- Sep 29, 2022
- Last posted
- Nov 9, 2022
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TorontoLead sponsor
- Zogenix, Inc.Collaborator
- University of TorontoReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.